Navigation Links
Henry Ford researchers identify genetic factors that may aid survival from brain cancer
Date:5/12/2014

DETROIT A Henry Ford Hospital research team has identified specific genes that may lead to improved survival of glioblastoma, the most common and deadly form of cancerous brain tumor.

The molecular data is expected to aid further research into genes that either help or impede the survival of patients diagnosed with the tumor, which can invade and rapidly grow in any part of the human brain.

"Studies such as ours that help define molecular alterations associated with short-term survival likely will help define the reasons why our current treatments don't succeed in these patients," says Dr. Steven Kalkanis, M.D., a neurosurgeon and surgical oncologist at Henry Ford's Hermelin Brain Tumor Center, and lead author of the study.

"As new mechanisms of resistance are revealed and targeted agents are developed to address these mechanisms, the number of long-term survivors should increase."

The Henry Ford study was published this month in the journal Clinical Neurology and Neurosurgery.

The study focused on 476 patients at Henry Ford Hospital who were diagnosed with glioblastoma from 1995 to 2008. Each was randomly chosen from the Hermelin Center's brain tumor tissue bank, which holds more than 4,100 unique patient brain tumor specimens.

The patients were evaluated as part of the international Cancer Genome Atlas, to which the Hermelin Brain Tumor Center at Henry Ford Hospital was a major contributor.

Besides noting a steady rise in survival rates over the 14 years examined in the study, researchers found that the median survival time among this group rose from 11.8 months in patients diagnosed from 1995 to 1999 to 15.9 months in those diagnosed from 2005 to 2008.

After categorizing each patient as a short (less than nine months), medium (nine to 24 months) or long-term (at least 24 months) survivor, the researchers looked for relationships between survival time and patient age, gender, functional impairment, increases in tumor size, surgery and chemotherapy.

They then performed a molecular analysis of each tumor specimen and explored its relationship to short- and long-term survival.

Besides confirming earlier studies that showed improved survival of glioblastoma as new techniques and medications were introduced, the new study found:

  • Survival times among Henry Ford patients were ahead of national glioblastoma survival trends.
  • Those age 70 and older included more short-term survivors that the younger age groups.
  • Gender differences were only detected when comparing the short- and medium-term survivors, with females more likely to be short-term survivors.
  • The tumor's location within the brain was not a significant factor in survival time.
  • Specific genes identified by the researchers may independently improve patient survival. The Henry Ford team concluded that more and ongoing research in this area is vital to understanding how to fight the usually fatal cancer tumor.

"Among the factors which are associated with increased survival of glioblastoma patients during the time period we studied," says Tom Mikkelsen, M.D., a neuro-oncologist and co-director of the Henry Ford's Hermelin Brain Tumor Center, "is the multidisciplinary care coordinated by a dedicated tumor board as common practice for managing brain tumor patients. New expertise in neurosurgery, molecular pathology and experimental therapeutics are critical and must be personalized for each patient."

While the medical community is engaged in an ongoing debate about the usefulness of such boards, Dr. Kalkanis says his team's research found that not only are they "warranted," but "necessary" for the future treatment of glioblastoma and continuing to improve patient quality of life and survival rates.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-850-3471
Henry Ford Health System
Source:Eurekalert

Related biology news :

1. Indiana University associate professor earns APSs Henry Pickering Bowditch Award
2. Oregon researchers capture handoff of tracked object between brain hemispheres
3. Homemade stink bug traps squash store-bought models, Virginia Tech researchers find
4. Ban cigarette filters to save the environment, suggest researchers
5. University of Toronto researchers find seeing Jesus in Toast phenomenon perfectly normal
6. Researchers find unique fore wing folding among Sub-Saharan African Ensign wasps
7. Penn State researchers believe ants can offer human-disease insights
8. Researchers find way to decrease chemoresistance in ovarian cancer
9. Researchers receive top honors for ecology paper
10. Researchers find the accelerator for molecular machines
11. Clemson researchers help track mysterious, endangered little devil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology: